Trinity Biotech plc
9.90%
3,424,019,957
888721
Apr 29, 2026
May 4, 2026, 04:19 PM
Reporting Persons (5)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Perceptive Advisors LLC | Investment Adviser | 9.90% | 3,424,019,957 | 0 | 3,424,019,957 |
| Perceptive Credit Advisors LLC | Investment Adviser | 9.90% | 3,424,019,957 | 0 | 3,424,019,957 |
| Joseph Edelman | Individual | 9.90% | 3,424,019,957 | 0 | 3,424,019,957 |
| Perceptive Credit Holdings II, L.P. | Partnership | 9.90% | 503,973,523 | 0 | 503,973,523 |
| Perceptive Credit Holdings III, L.P. | Partnership | 9.90% | 2,920,046,434 | 0 | 2,920,046,434 |
Disclosure Items (5)
Class A Ordinary Shares, $0.0001 par value per share
Trinity Biotech plc
IDA Business Park, Bray, Co. Wicklow, L2, A98 H5C8
Items 5(a)-(b) of the Schedule 13D is amended and supplemented as follows: The information set forth in the cover pages to this Amendment No. 8 to the Schedule 13D is incorporated by reference. The percentage set forth in row 13 is based on 374,206,640 Ordinary Shares outstanding, as reported in the Issuer's Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 30, 2026, and assumes the exercise of all Warrants and the conversion of the Convertible Note, the Milestone Payment Obligation and the Contingent Payment Obligation to the extent permitted by the Beneficial Ownership Cap.
The Information set forth in Item 5(a) is incorporated herein by reference.
Item 6 of the Schedule 13D is amended and supplemented as follows: The information included in Item 4 above is incorporated by reference into this Item 6.
Item 7 of the Schedule 13D is amended and supplemented as follows: Exhibit 11 Limited Waiver and Third Amendment to Credit Agreement, dated as of April 30, 2026, by and among Trinity Biotech PLC, Trinity Biotech, Inc., Fitzgerald Industries International, Inc., Clark Laboratories, Inc. (D/B/A Trinity Biotech (USA)), Biopool U.S., Inc. (D/B/A Trinity Biotech Distribution), Primus Corporation, Mardx Diagnostics, Inc. and Immco Diagnostics, Inc. as borrowers, Trinity Biotech PLC and Certain of its Subsidiaries as Guarantors and Perceptive Credit Holdings III, LP, as Administrative Agent (incorporated by reference Exhibit 4.18.4 to the Company's report on Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 30, 2026). Exhibit 12 Amended and Restated Senior Convertible Note, dated as of April 30, 2026, by and among Trinity Biotech PLC, Trinity Biotech, Inc., Fitzgerald Industries International, Inc., Clark Laboratories, Inc. (D/B/A Trinity Biotech (USA)), Biopool U.S., Inc. (D/B/A Trinity Biotech Distribution), Primus Corporation, Mardx Diagnostics, Inc. and Immco Diagnostics, Inc. and Perceptive Credit Holdings III, LP (incorporated by reference Exhibit 4.19 to the Company's report on Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 30, 2026). Exhibit 13 Amendment No. 1 to Conversion Rights Agreement, dated as of April 30, 2026, by and among Trinity Biotech PLC, TRIB Biosensors Inc. and Perceptive Credit Holdings II, LP (incorporated by reference Exhibit 4.20.2 to the Company's report on Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 30, 2026).